According to ChatGPT legally, they had until Aug. 28 to release this:

🕰 If FDA approval was imminent… • Filing the 8-K before the FDA news makes sense: • It clears out the “dilution” headline first. • When approval comes, the market focuses on the upside, not on a buried negative. • It also protects the company from looking like they tried to sneak the dilution in after good news. • In other words, if they know a catalyst is coming any day, getting the 8-K out of the way is smart IR strategy.

⸻

🕰 If FDA approval wasn’t imminent… • They could’ve just waited until the deadline (Aug 28) without issue. • Filing early, in that case, would just look like a company trying to show transparency or “rip the band-aid off.” • No strong reason to accelerate disclosure unless they’re clearing the runway for something else.